Altered neural avalanche spreading in people with drug-resistant epilepsy✰
B M Sancetta1, M A G Matarrese2, L Ricci1
1Research Unit of Neurology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, Rome 00128, Italy; Operative Research Unit of Neurology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, Roma 00128, Italy.
Objective:
To characterize a peculiar "EEG endophenotype" of drug-resistant epilepsy (DRE) through the graph theory characterization of avalanche spatiotemporal spreading properties.
Methods:
We performed avalanche analysis and computed avalanche transition matrices (ATMs) on 19-channel scalp EEG of 120 people with epilepsy (60 DRE and 60 non-DRE) who assumed two anti-seizure medications, comparing such results with a group of 40 healthy subjects (HS). Network topologies of ATMs were characterized through graph theory metrics. We performed an analysis of variance to compare aperiodic metrics between HS, DRE and non-DRE. Logistic regression was performed to test and compare the ability of graph theory metrics on ATM and clinical features to correctly discriminate the PwE group according to the clinical outcome (DRE or non-DRE).
Results:
DRE exhibited a peculiar altered avalanche spreading as proved by the higher mean betweenness centrality, the longer characteristic path length and the lower small-world index (more regular and less plastic network topology) of ATMs than non-DRE and HS (p-values from <0.001 to 0.05). Graph metrics on ATMs significantly improved the yield of detecting DRE and contributed the most to the model accuracy (0.83) than clinical features. Resting-state EEG activity of HS and PwE did not deviate from the characteristics of a system operating at criticality.
Conclusions:
ATMs detect alterations of resting-state networks peculiar to the DRE condition.
Significance:
These findings could open new scenarios for the future identification of promising biomarkers of DRE through scalp EEG.
More Related Videos
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
